Skip to main content
. Author manuscript; available in PMC: 2015 Apr 17.
Published in final edited form as: Head Neck. 2013 Jun 1;36(3):375–384. doi: 10.1002/hed.23316

Figure 1.

Figure 1

Figure 1

Src inhibitors suppress the phosphorylations of Src and FAK. (A) TPC-1 (top) and K2 (bottom) cells were treated with PP2, SU6656, or dasatinib for 1 h at 37°C with indicated concentrations. Protein extracts were prepared and the expressions of p-Src and total Src were detected by Western blot analysis. (B) TPC-1 (top) and K2 (bottom) cells were treated with PP2 (5 or 10 μM), SU6656 (5 or 10 μM), or dasatinib (0.01 or 0.1 μM) for 1-96 hours. Protein extracts were prepared and incubated with antibodies against p-Src and p-FAK (Tyr861) on Western blot analysis. Total Src and FAK were used as loading controls. Cells treated with DMSO only were used as positive controls for normal expression of p-Src and p-FAK (Tyr861).